What Pharmako Biotechnologies does

Pharmako Biotechnologies is a privately held Australian B2B nutraceutical technology company that develops and manufactures advanced delivery systems for lipophilic (fat-soluble) active ingredients. Founded in 2015 and headquartered in Frenchs Forest, Sydney, the company serves nutraceutical, cosmeceutical, and functional food manufacturers globally, with products distributed in over 30 countries. The company is staffed by 11–50 employees and operates a Therapeutic Goods Administration (TGA)-licensed manufacturing facility with five in-house laboratories spanning R&D, wet labs, and testing; co-founder and commercial director Eric Meppem leads the commercial function.

Name

Pharmako Biotechnologies

Legal name

Pharmako Biotechnologies Pty. Ltd.

Website

https://pharmako.com.au

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Pharmako Biotechnologies is a Sydney-based B2B developer and manufacturer of patented delivery systems — AquaCelle, LipiSperse, CPO, and PlexoZome — that enhance the bioavailability of lipophilic nutraceutical, cosmeceutical, and functional food ingredients distributed in over 30 countries.

Ownership category

akta.pro rank

Product category

Nutraceutical Delivery Systems & Bioavailability Ingredients

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Delivery Systems & Encapsulation (Microencapsulation, Liposomes, Emulsions, Beadlets, Spray-Dried) (AFAJAKAL)

akta.pro secondary industry

Encapsulation & Emulsified Delivery Systems (Spray-dried emulsions, Lipid microencapsulation) (AFAJACAL)

Keywords

• Nutraceutical delivery systems
• Lipid bioavailability technology
• Self micro emulsifying systems
• Cold water dispersion technology
• Liposomal delivery technology

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales

Revenue model

1. Ingredient/Technology Licensing and Supply: Pharmako manufactures and supplies enhanced ingredients using their proprietary delivery technologies to nutraceutical, cosmeceutical and functional food companies. They offer both their own developed ingredients (Optimised Ingredients) and partnered ingredients through their global distributor network.
2. Contract Manufacturing (TGA Licensed): Manufacturing on-site in their Therapeutic Goods Administration (TGA) licensed facility allows customisation of technologies to customer requirements, offering solutions ranging from powders, liquids, premixes and capsules.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Pharmako Biotechnologies develops, manufactures and supplies proprietary advanced delivery systems and enhanced nutraceutical ingredients to B2B customers. Its portfolio comprises four patented delivery technology platforms (AquaCelle®, LipiSperse®, CPO® and PlexoZome®) applied to a range of optimised ingredients (e.g., HydroCurc®, VeriSperse®, BioBerb®, AquaCelle® Omega-3, AquaCelle® CoQ10, CPO® Astaxanthin, CPO® Lavender Oil, LipiSperse® Quercetin) plus distributed partnered ingredients (Levagen®+, Libifem®, Tesnor®, Testofen®, Trigogen®, Slimaluma®). Manufacturing is performed in-house at a TGA-licensed facility in Sydney, with outputs sold as powders, liquids, premixes and capsules to nutraceutical, cosmeceutical and functional food manufacturers globally.

Product overview

Pharmako Biotechnologies is a nutraceutical delivery systems company offering a portfolio of advanced delivery technologies, optimised ingredients, and partnered ingredients. The core technology portfolio includes four delivery system platforms: AquaCelle® (self micro-emulsifying delivery system/SMEDDS), LipiSperse® (cold water dispersion technology), CPO® (Compressible Powdered Oils), and PlexoZome® (liposomal delivery technology). These delivery systems are applied to create optimised ingredients including AquaCelle® CoQ10 (3x+ absorption), AquaCelle® Omega-3 (6x+ absorption), BioBerb® (berberine with 3x bioavailability), HydroCurc® (curcumin with LipiSperse®), VeriSperse® (resveratrol with 2x bioavailability), LipiSperse® Quercetin, CPO® Astaxanthin, and CPO® Lavender Oil. The partnered ingredients portfolio includes Levagen®+ (PEA with LipiSperse®), Libifem® (female sexual health), Tesnor® (testosterone support), Testofen® (fenugreek testosterone support), Trigogen® (blood sugar support), and Slimaluma® (appetite suppression/weight management). The company operates from a TGA-licensed manufacturing facility in Sydney, Australia.

Differentiator

Problem solved

Functional benefit

Brands

• AquaCelle®: Award-winning, customisable, self micro-emulsifying delivery system (SMEDS) designed to optimise bioavailability of oily lipophilic active ingredients such as ubiquinol, omega-3s, lutein and resveratrol whilst maintaining product stability.
• LipiSperse®
• CPO®
• PlexoZome®

Products and services

• AquaCelle® Customisable SMEDDS platform technology licensed and supplied to nutraceutical, cosmeceutical and functional food manufacturers for improving the bioavailability of lipophilic active ingredients.
• LipiSperse® Cold water dispersion technology platform for dispersing solid/powder lipophilic active ingredients in cold water with high active loading for nutraceutical and functional food manufacturers.
• CPO® (Compressible Powdered Oils) Oil-to-powder conversion technology platform that converts oily lipid-based ingredients into stable compressible powders for tablet and powder formulations without oil leaching.
• PlexoZome® Liposomal delivery technology platform that produces customisable stable liquid liposomal formulations verified by DLS testing, Zeta potential and Cryo-TEM imaging.
• AquaCelle® Omega-3 Optimised omega-3 ingredient using AquaCelle SMEDDS technology, enhancing DHA and EPA bioavailability by over 600% for nutraceutical manufacturers.
• AquaCelle® CoQ10 Optimised ubiquinone CoQ10 ingredient using AquaCelle SMEDDS technology, delivering over 300% improved bioavailability versus standard ubiquinone for nutraceutical manufacturers.
• HydroCurc® Cold water dispersible curcumin ingredient using LipiSperse technology, with multiple cognitive-function, botanical and sports nutrition industry awards.
• VeriSperse® Optimised trans-resveratrol ingredient using LipiSperse technology, delivering twice the bioavailability of standard resveratrol for nutraceutical manufacturers.
• BioBerb® Enhanced berberine ingredient using LipiSperse technology, delivering 3x more bioavailability than competitor berberine for nutraceutical manufacturers.
• LipiSperse® Quercetin Cold water dispersible quercetin ingredient using LipiSperse technology to increase bioavailability and functionality for nutraceutical manufacturers.
• CPO® Astaxanthin Optimised astaxanthin powder combining AquaCelle and CPO technologies, showing 2-fold greater absorption than standard astaxanthin for nutraceutical manufacturers.
• CPO® Lavender Oil Lavender oil powder combining AquaCelle and CPO technologies, doubling absorption versus standard lavender oil and enabling tableting.
• Levagen®+ Distributed partnered ingredient: cold water dispersible PEA using LipiSperse technology, with 1.75x the absorption of standard PEA, marketed for sports nutrition and healthspan applications.
• Libifem® Distributed partnered ingredient: standardised fenugreek extract supporting female sexual health, menopause symptom relief and muscle strength.
• Tesnor® Distributed partnered ingredient: proprietary cocoa bean and pomegranate peel extract blend supporting testosterone production and aromatase inhibition.
• Testofen® Distributed partnered ingredient: patented fenugreek extract standardised for 50% Fenuside, supporting testosterone, vitality, muscle and sports performance in men.
• Trigogen® Distributed partnered ingredient: fenugreek seed extract standardised to trigonelline for blood sugar and gut health support.
• Slimaluma® Distributed partnered ingredient: patented Caralluma Fimbriata extract supporting appetite suppression and weight management.
• TGA-licensed Contract Manufacturing TGA-licensed contract manufacturing service enabling customers to commission customised delivery technology solutions in powder, liquid, premix and capsule formats at the company's Sydney facility.

Quantifiable outcome

• AquaCelle Omega-3 improves EPA and DHA bioavailability by over 600%
• +6 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

One partnership is on record.

• Saanroo (formerly Gencor)coreChannel Partner/ Reseller/ DistributorSaanroo (previously Gencor) serves as Pharmako's global distributor for enhanced ingredients including HydroCurc, PlexoZome NR, VeriSperse, AquaCelle Omega-3, Levagen+, Testofen, and Libifem. The partnership involves significant competitive advantages in the marketplace through strategic research and development alignment.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Gencor Pacific (Saanroo): Pharmako's exclusive global distribution partner and co-developer of multiple partnered ingredients (Levagen+, Testofen, Libifem, Tesnor, Slimaluma). Operates as a nutraceutical ingredient supplier of comparable size with overlapping product portfolio and customer base.
• Lipoid GmbH: Specialty phospholipid and liposomal delivery systems manufacturer serving pharma, cosmetics and nutrition. Directly comparable to Pharmako's PlexoZome® liposomal technology platform and similar in size and focus.
• ABITEC Corporation: Specialty lipid and functional ingredient manufacturer for nutraceutical, pharmaceutical and personal care markets. Comparable to Pharmako in providing lipid-based delivery solutions for lipophilic actives.
• PLT Health Solutions: Ingredient solutions company offering clinically-supported branded ingredients to the nutraceutical industry. Comparable business model — combines proprietary delivery/ingredient technologies with B2B sales to supplement manufacturers.
• Bioiberica: Specialty bioactive ingredient manufacturer with focus on joint, mobility and immune health. Comparable as a science-led, B2B nutraceutical ingredient supplier serving global supplement brands with proprietary ingredient platforms.

Broad incumbents

• Kerry Group: Global taste and nutrition major with a ProActive Health portfolio that includes bioavailability and delivery system technologies. A larger incumbent with overlapping capabilities to Pharmako's delivery platforms across food, beverage and supplement end-markets.
• Evonik Industries: Specialty chemicals company with pharma and nutrition delivery platforms (e.g., EUDRAGUARD, lipids). A broad incumbent whose delivery-system portfolio competes with Pharmako's technology stack at much larger scale.
• DSM-Firmenich: Global nutrition, health and beauty ingredients major with a broad delivery-systems portfolio across vitamins, omega-3 and bioactive ingredients. A broad incumbent against which Pharmako's specialty delivery platforms must differentiate on clinical evidence.
• Lonza: Pharma and nutrition CDMO with capsule and ingredient delivery platforms (formerly Capsugel). Operates at much larger scale in pharma-grade delivery systems adjacent to Pharmako's TGA-licensed operations.
• Cargill Health Technologies: Global food and ingredient major with an active delivery-system and bioavailability-enhancement agenda across food, beverage and supplement channels. A broad incumbent whose scale and supply-chain depth dwarfs Pharmako's specialty operation.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pharmako-biotechnologies-pty-ltd

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pharmako Biotechnologies